CHARLESLUCHARLES LU8810LU, CHARLESProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson24980784Stewart DJ, Chang DW, Ye Y, Spitz M, Lu C, Shu X, Wampfler JA, Marks RS, Garces YI, Yang P, Wu XThe pharmacogenomics journalWnt signaling pathway pharmacogenetics in non-small cell lung cancer. Pharmacogenomics J. 2014 Dec; 14(6):509-22.Pharmacogenomics J2014-07-01T00:00:002014Wnt signaling pathway pharmacogenetics in non-small cell lung cancer.1400 Holcombe BlvdHouston77030-4008TXAuthorship 1748254Authorship 1748775Authorship 1751071Authorship 1751456Authorship 1756143Authorship 1768283Authorship 1772534Authorship 1781224Authorship 1787894Authorship 1790674Authorship 1801683Authorship 1804522Authorship 1806262Authorship 1839443Authorship 1852797Authorship 1854017Authorship 18656016Authorship 1869769Authorship 1871775Authorship 1878293Authorship 18798611Authorship 1884493Authorship 1891092Authorship 1893823Authorship 1898022Authorship 19131512Authorship 1921018Authorship 1945847Authorship 1946014Authorship 1949313Authorship 1958001215725609Gu J, Liang D, Wang Y, Lu C, Wu XMutation researchEffects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res. 2005 Mar 07; 581(1-2):97-104.Mutat Res2004-12-16T00:00:002004Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians.20094773Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RSInvestigational new drugsPharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs. 2011 Jun; 29(3):499-505.Invest New Drugs2010-01-22T00:00:002010Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).21285393Mendoza TR, Wang XS, Lu C, Palos GR, Liao Z, Mobley GM, Kapoor S, Cleeland CSThe oncologistMeasuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist. 2011; 16(2):217-27.Oncologist2011-02-01T00:00:002011Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory.21437893Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JDCancerPhase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011 Oct 15; 117(20):4707-13.Cancer2011-03-22T00:00:002011Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer.22079735Jiang ZQ, Yang K, Komaki R, Wei X, Tucker SL, Zhuang Y, Martel MK, Vedam S, Balter P, Zhu G, Gomez D, Lu C, Mohan R, Cox JD, Liao ZInternational journal of radiation oncology, biology, physicsLong-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):332-9.Int J Radiat Oncol Biol Phys2011-11-11T00:00:002011Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.23371797Barney BJ, Wang XS, Lu C, Liao Z, Johnson VE, Cleeland CS, Mendoza TRQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationPrognostic value of patient-reported symptom interference in patients with late-stage lung cancer. Qual Life Res. 2013 Oct; 22(8):2143-50.Qual Life Res2013-01-31T00:00:002013Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer.Endocrine Neoplasia & HDEpidemiologyLeukemiaRadiation OncologySymptom Research CAOThoracic Head & Neck Medical OncologyTranslational Molecular PathologyMD AndersonXIFENGWUXIFENG WU8625WU, XIFENGProfessorJOE YCHANGJOE Y CHANG8639CHANG, JOE YProfessorJOHN VICTORHEYMACHJOHN VICTOR HEYMACH9280HEYMACH, JOHN VICTORProfessorDANIELGOMEZDANIEL GOMEZ9621GOMEZ, DANIELAssociate ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorGEORGE RBLUMENSCHEINGEORGE R BLUMENSCHEIN8741BLUMENSCHEIN, GEORGE RProfessor1.774350.0046958438research areas2.379470.0200273177coauthor of75.779516.418160similar to11121selected publicationsMARIA ECABANILLASMARIA E CABANILLAS8975CABANILLAS, MARIA EAssociate ProfessorCHARLESCLEELANDCHARLES CLEELAND8701CLEELAND, CHARLESProfessorIGNACIO IVANWISTUBAIGNACIO IVAN WISTUBA9098WISTUBA, IGNACIO IVANProfessorAuthorship 22090113Authorship 22127710Authorship 2223631Authorship 2254224Authorship 227780115050312Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JDInternational journal of radiation oncology, biology, physicsEffects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77.Int J Radiat Oncol Biol Phys2004-04-01T00:00:002004Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.15131032Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WKClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004 May 01; 10(9):2968-76.Clin Cancer Res2004-05-01T00:00:002004Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.16092602Lu C, Gonzalez RG, Jolesz FA, Wen PY, Talcott JAThe journal of supportive oncologySuspected spinal cord compression in cancer patients: a multidisciplinary risk assessment. J Support Oncol. 2005 Jul-Aug; 3(4):305-12.J Support Oncol2005-07-01T00:00:002005Suspected spinal cord compression in cancer patients: a multidisciplinary risk assessment.17960324Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SRInvestigational new drugsPhase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008 Feb; 26(1):81-7.Invest New Drugs2007-10-25T00:00:002007Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.20505152Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJJournal of the National Cancer InstituteChemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst. 2010 Jun 16; 102(12):859-65.J Natl Cancer Inst2010-05-26T00:00:002010Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.25207766Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mr?zek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CGThe New England journal of medicineTargetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 Sep 11; 371(11):1005-15.N Engl J Med2014-09-11T00:00:002014Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.Authorship 2402401Authorship 2414237Authorship 2448472Authorship 2449701Authorship 2450473Authorship 2464535Authorship 2477461Authorship 2488702Authorship 2551393Authorship 2553538Authorship 2575926Authorship 2582634Authorship 2586626Authorship 25965698001315Lu C, Ridker PMClinical cardiologyEchocardiographic diagnosis of congenital absence of the pericardium in a patient with VATER association defects. Clin Cardiol. 1994 Sep; 17(9):503-4.Clin Cardiol1994-09-01T00:00:001994Echocardiographic diagnosis of congenital absence of the pericardium in a patient with VATER association defects.9926972Talcott JA, Stomper PC, Drislane FW, Wen PY, Block CC, Humphrey CC, Lu C, Jolesz FSupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerAssessing suspected spinal cord compression: a multidisciplinary outcomes analysis of 342 episodes. Support Care Cancer. 1999 Jan; 7(1):31-8.Support Care Cancer1999-01-01T00:00:001999Assessing suspected spinal cord compression: a multidisciplinary outcomes analysis of 342 episodes.11714540Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, Jung M, Hong WK, Herbst RSLung cancer (Amsterdam, Netherlands)A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer. 2001 Dec; 34(3):427-32.Lung Cancer2001-12-01T00:00:002001A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.12124835Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JSCancerThe novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53.Cancer2002-07-15T00:00:002002The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.12796372Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossella FV, Glisson BSClinical cancer research : an official journal of the American Association for Cancer ResearchA phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res. 2003 Jun; 9(6):2085-91.Clin Cancer Res2003-06-01T00:00:002003A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.15447998Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, Hong WK, Mao LClinical cancer research : an official journal of the American Association for Cancer ResearchValue of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6119-25.Clin Cancer Res2004-09-15T00:00:002004Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.15908659Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DMJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol. 2005 May 20; 23(15):3495-501.J Clin Oncol2005-05-20T00:00:002005Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.16399440Wu X, Lu C, Chiang SS, Ajani JASeminars in oncologyPharmacogenetics in esophageal cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S87-9.Semin Oncol2005-12-01T00:00:002005Pharmacogenetics in esophageal cancer.19852033Wang XS, Shi Q, Lu C, Basch EM, Johnson VE, Mendoza TR, Mobley GM, Cleeland CSCancerPrognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer. 2010 Jan 01; 116(1):137-45.Cancer2010-01-01T00:00:002010Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer.21264827Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JDCancerEarly findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011 Jul 01; 117(13):3004-13.Cancer2011-01-24T00:00:002011Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer.21931024Talcott JA, Yeap BY, Clark JA, Siegel RD, Loggers ET, Lu C, Godley PAJournal of clinical oncology : official journal of the American Society of Clinical OncologySafety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol. 2011 Oct 20; 29(30):3977-83.J Clin Oncol2011-09-19T00:00:002011Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.22412901Chen X, Gorlov IP, Ying J, Merriman KW, Kimmel M, Lu C, Reyes-Gibby CC, Gorlova OYPloS oneInitial medical attention on patients with early-stage non-small cell lung cancer. PLoS One. 2012; 7(3):e32644.PLoS One2012-03-07T00:00:002012Initial medical attention on patients with early-stage non-small cell lung cancer.22665541Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, J?nne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EEJournal of clinical oncology : official journal of the American Society of Clinical OncologyMulticenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.J Clin Oncol2012-06-04T00:00:002012Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.23300016Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DRAnnals of oncology : official journal of the European Society for Medical OncologyImproved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol. 2013 May; 24(5):1312-9.Ann Oncol2013-01-08T00:00:002013Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy.Authorship 2675732Authorship 271076117445470Wang J, Lu C, Liu XY, Zhang HB, Zhao J, Yang L, Guo QZ, An TT, Wu MNZhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases[Distinguishing second primary tumors from lung metastasis in patients with postoperative non-small cell lung cancer by microsatellite analysis]. Zhonghua Jie He He Hu Xi Za Zhi. 2007 Feb; 30(2):103-7.Zhonghua Jie He He Hu Xi Za Zhi2007-02-01T00:00:002007[Distinguishing second primary tumors from lung metastasis in patients with postoperative non-small cell lung cancer by microsatellite analysis].22558101Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JAPloS onePhase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833.PLoS One2012-04-25T00:00:002012Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.Authorship 2727121Authorship 27526513Authorship 2766751Authorship 27759839879774Lu C, Stomper PC, Drislane FW, Wen PY, Block CC, Humphrey CC, Collins CA, Jolesz F, Talcott JABreast cancer research and treatmentSuspected spinal cord compression in breast cancer patients: a multidisciplinary risk assessment. Breast Cancer Res Treat. 1998 Sep; 51(2):121-31.Breast Cancer Res Treat1998-09-01T00:00:001998Suspected spinal cord compression in breast cancer patients: a multidisciplinary risk assessment.15184994Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RSCancer chemotherapy and pharmacologyClinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol. 2004 Oct; 54(4):308-14.Cancer Chemother Pharmacol2004-06-04T00:00:002004Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.15542809Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK, Khuri FRJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol. 2004 Nov 15; 22(22):4575-83.J Clin Oncol2004-11-15T00:00:002004Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.23721245Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick SCThyroid : official journal of the American Thyroid AssociationRandomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014 Feb; 24(2):232-40.Thyroid2013-09-10T00:00:002013Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.Authorship 2809379Authorship 28101210Authorship 2909583Authorship 29825413Authorship 3020474Authorship 303828925054431Pu X, Wang L, Chang JY, Hildebrandt MA, Ye Y, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu XClinical pharmacology and therapeuticsInflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer. Clin Pharmacol Ther. 2014 Nov; 96(5):609-15.Clin Pharmacol Ther2014-07-23T00:00:002014Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer.25170640Fagundes C, Jones D, Vichaya E, Lu C, Cleeland CSJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerSocioeconomic status is associated with depressive severity among patients with advanced non-small-cell lung cancer: treatment setting and minority status do not make a difference. J Thorac Oncol. 2014 Oct; 9(10):1459-63.J Thorac Oncol2014-10-01T00:00:002014Socioeconomic status is associated with depressive severity among patients with advanced non-small-cell lung cancer: treatment setting and minority status do not make a difference.26025965Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou VAnnals of oncology : official journal of the European Society for Medical OncologyPhase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1476-80.Ann Oncol2015-05-29T00:00:002015Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.26028228Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, Allen PK, Mehran RJ, Lu C, Gillin M, Liao Z, Cox JDRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyLong-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol. 2015 Jun; 115(3):367-72.Radiother Oncol2015-05-28T00:00:002015Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.26403258Gunn GB, Hansen CC, Garden AS, Fuller CD, Mohamed AS, Morrison WH, Frank SJ, Beadle BM, Phan J, Chronowski GM, Sturgis EM, Lewis CM, Lu C, Hutcheson KA, Mendoza TR, Cleeland CS, Rosenthal DIRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyFavorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. Radiother Oncol. 2015 Oct; 117(1):132-8.Radiother Oncol2015-09-21T00:00:002015Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study.26568552Cabanillas ME, Dadu R, Hu MI, Lu C, Gunn GB, Grubbs EG, Lai SY, Williams MDHematology/oncology clinics of North AmericaThyroid Gland Malignancies. Hematol Oncol Clin North Am. 2015 Dec; 29(6):1123-43.Hematol Oncol Clin North Am2015-12-01T00:00:002015Thyroid Gland Malignancies.74Professor14Associate Professor15718477Schabath MB, Delclos GL, Martynowicz MM, Greisinger AJ, Lu C, Wu X, Spitz MRAmerican journal of epidemiologyOpposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol. 2005 Mar 01; 161(5):412-22.Am J Epidemiol2005-03-01T00:00:002005Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk.23840350Yuan X, Wei Q, Komaki R, Liu Z, Yang J, Tucker SL, Xu T, Heymach JV, Lu C, Cox JD, Liao ZPloS oneTGF?1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. PLoS One. 2013; 8(6):e65659.PLoS One2013-06-19T00:00:002013TGF?1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy.26901225Zhao L, Pu X, Ye Y, Lu C, Chang JY, Wu XCancersAssociation between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer. Cancers (Basel). 2016 Feb 18; 8(2).Cancers (Basel)2016-02-18T00:00:002016Association between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer.17189404Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu XClinical cancer research : an official journal of the American Association for Cancer ResearchAberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Dec 15; 12(24):7329-38.Clin Cancer Res2006-12-15T00:00:002006Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer.17627019Xing J, Spitz MR, Lu C, Zhao H, Yang H, Wang W, Stewart DJ, Wu XCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyDeficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1517-22.Cancer Epidemiol Biomarkers Prev2007-07-01T00:00:002007Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis.18235119Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EB, Shih YC, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston KJournal of clinical oncology : official journal of the American Society of Clinical OncologyOutcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol. 2008 Feb 01; 26(4):606-11.J Clin Oncol2008-02-01T00:00:002008Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.20530316Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T?n PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison MLThe New England journal of medicineHuman papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 01; 363(1):24-35.N Engl J Med2010-06-07T00:00:002010Human papillomavirus and survival of patients with oropharyngeal cancer.20811626Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu XPloS oneGenetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010 Aug 25; 5(8):e12402.PLoS One2010-08-25T00:00:002010Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer.21515830Lin M, Stewart DJ, Spitz MR, Hildebrandt MA, Lu C, Lin J, Gu J, Huang M, Lippman SM, Wu XCarcinogenesisGenetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis. 2011 Jul; 32(7):1050-6.Carcinogenesis2011-04-22T00:00:002011Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.21690477Cleeland CS, Mendoza TR, Wang XS, Woodruff JF, Palos GR, Richman SP, Nazario A, Lynch GR, Liao KP, Mobley GM, Lu CJournal of clinical oncology : official journal of the American Society of Clinical OncologyLevels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center. J Clin Oncol. 2011 Jul 20; 29(21):2859-65.J Clin Oncol2011-06-20T00:00:002011Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center.21698121Dai J, Gu J, Lu C, Lin J, Stewart D, Chang D, Roth JA, Wu XPloS oneGenetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PLoS One. 2011; 6(6):e21120.PLoS One2011-06-17T00:00:002011Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer.Authorship 3744203Authorship 3746255Authorship 3746289Authorship 374631618414412Xing J, Stewart DJ, Gu J, Lu C, Spitz MR, Wu XBritish journal of cancerExpression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1716-22.Br J Cancer2008-04-15T00:00:002008Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer.18854777Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, Gu J, Hong WK, Stewart D, Spitz MRPharmacogenetics and genomicsGermline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics. 2008 Nov; 18(11):955-65.Pharmacogenet Genomics2008-11-01T00:00:002008Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy.27785980Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas METhyroid : official journal of the American Thyroid AssociationReal-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 2017 01; 27(1):81-87.Thyroid2016-11-29T00:00:002016Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.28026871Pezzi TA, Mohamed ASR, Sheu T, Blanchard P, Sandulache VC, Lai SY, Cabanillas ME, Williams MD, Pezzi CM, Lu C, Garden AS, Morrison WH, Rosenthal DI, Fuller CD, Gunn GBCancerRadiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer. 2017 05 01; 123(9):1653-1661.Cancer2016-12-27T00:00:002016Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.28068873Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas METhyroid : official journal of the American Thyroid AssociationPatterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017 05; 27(5):672-681.Thyroid2017-02-16T00:00:002017Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.20447721Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu XLung cancer (Amsterdam, Netherlands)PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer. 2011 Jan; 71(1):82-8.Lung Cancer2010-05-05T00:00:002010PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.21965272Yin J, Lu C, Gu J, Lippman SM, Hildebrandt MA, Lin J, Stewart D, Spitz MR, Wu XCarcinogenesisCommon genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. Carcinogenesis. 2011 Dec; 32(12):1867-71.Carcinogenesis2011-09-28T00:00:002011Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer.21483023Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang PJournal of the National Cancer InstituteGenome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011 May 18; 103(10):817-25.J Natl Cancer Inst2011-04-11T00:00:002011Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.Authorship 845679Authorship 852691Authorship 853472Authorship 856828Authorship 857981Authorship 858311Authorship 859844Authorship 860836Authorship 865626CancerErratum. Cancer. 97:1367.Erratum22665367Lin J, Lu C, Stewart DJ, Gu J, Huang M, Chang DW, Lippman SM, Wu XCarcinogenesisSystematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk. Carcinogenesis. 2012 Sep; 33(9):1699-706.Carcinogenesis2012-06-04T00:00:002012Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk.Chemotherapy and molecularly targeted agents for advanced non-small-cell lung cancer. 103-113.Chemotherapy and molecularly targeted agents for advanced non-small-cell lung cancerPLoS OneTGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. PLoS One. 8.TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive RadiotherapyThyroidReal-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 27:81-87.Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid CarcinomaEstablishing a GMP manufacturing site for nanoparticles. 413-416.Establishing a GMP manufacturing site for nanoparticlesCancersAssociation between genetic variants in DNA double-strand break repair pathways and risk of radiation therapy-induced pneumonitis and esophagitis in non-small cell lung cancer. Cancers. 8.Association between genetic variants in DNA double-strand break repair pathways and risk of radiation therapy-induced pneumonitis and esophagitis in non-small cell lung cancerJournal of Pain and Symptom ManagementDexamethasone for Dyspnea in Cancer Patients. Journal of Pain and Symptom Management. 52:8-16.e1.Dexamethasone for Dyspnea in Cancer PatientsRadiotherapy and OncologyFavorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa. Radiotherapy and Oncology. 117:132-138.Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossaCancerRadiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma. Cancer. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma15837739Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu XClinical cancer research : an official journal of the American Association for Cancer ResearchHigh mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8.Clin Cancer Res2005-04-15T00:00:002005High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy.16342067Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR, Hong WK, Wu XCancerAssociation between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006 Jan 15; 106(2):441-7.Cancer2006-01-15T00:00:002006Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma.16926177Gu J, Gong Y, Huang M, Lu C, Spitz MR, Wu XCarcinogenesisPolymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis. 2007 Feb; 28(2):350-5.Carcinogenesis2006-08-21T00:00:002006Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians.17020976Lin X, Gu J, Lu C, Spitz MR, Wu XClinical cancer research : an official journal of the American Association for Cancer ResearchExpression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Oct 01; 12(19):5720-5.Clin Cancer Res2006-10-01T00:00:002006Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer.17582598Yang H, Spitz MR, Stewart DJ, Lu C, Gorlov IP, Wu XInternational journal of cancerATM sequence variants associate with susceptibility to non-small cell lung cancer. Int J Cancer. 2007 Nov 15; 121(10):2254-9.Int J Cancer2007-11-15T00:00:002007ATM sequence variants associate with susceptibility to non-small cell lung cancer.17908995Wang W, Spitz MR, Yang H, Lu C, Stewart DJ, Wu XClinical cancer research : an official journal of the American Association for Cancer ResearchGenetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res. 2007 Oct 01; 13(19):5974-81.Clin Cancer Res2007-10-01T00:00:002007Genetic variants in cell cycle control pathway confer susceptibility to lung cancer.Authorship 8864789Authorship 88753512Authorship 8879984Authorship 88818910Authorship 8890384D013964Disorders36218630.446867Thyroid NeoplasmsD002289Disorders64653060.283287Carcinoma, Non-Small-Cell LungD008175Disorders1353114820.198988Lung NeoplasmsAuthorship 9085256Authorship 9128297Authorship 9142186Authorship 91584416Authorship 9213025Authorship 92616410Authorship 9264796Authorship 92923119Authorship 9316771426165417Tang C, Lee MS, Gomez D, Levy LB, Zhuang Y, Lu C, Liao Z, Komaki RAmerican journal of clinical oncologyEffects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer. Am J Clin Oncol. 2017 Dec; 40(6):625-630.Am J Clin Oncol2017-12-01T00:00:002017Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.27330023Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, Lu C, William W, Pisters K, Eapen G, Fossella F, Amin S, Bruera EJournal of pain and symptom managementDexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. J Pain Symptom Manage. 2016 07; 52(1):8-16.e1.J Pain Symptom Manage2016-06-18T00:00:002016Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial.28727865Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, Li H, Mohan R, Heymach JV, Vaporciyan AA, Hahn S, Cox JDJAMA oncologyProton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.JAMA Oncol2017-08-10T00:00:002017Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.28346771Reyes-Gibby CC, Melkonian SC, Hanna EY, Yeung SJ, Lu C, Chambers MS, Banala SR, Gunn GB, Shete SSHead & neckCohort study of oncologic emergencies in patients with head and neck cancer. Head Neck. 2017 06; 39(6):1195-1204.Head Neck2017-03-27T00:00:002017Cohort study of oncologic emergencies in patients with head and neck cancer.28452157Cabanillas ME, Williams MD, Gunn GB, Weitzman SP, Burke L, Busaidy NL, Ying AK, Yiin YH, William WN, Lu C, Lai SYHead & neckFacilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head Neck. 2017 07; 39(7):1291-1295.Head Neck2017-04-28T00:00:002017Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer.28678827Reyes-Gibby CC, Melkonian SC, Wang J, Yu RK, Shelburne SA, Lu C, Gunn GB, Chambers MS, Hanna EY, Yeung SJ, Shete SPloS oneIdentifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis. PLoS One. 2017; 12(7):e0180396.PLoS One2017-07-05T00:00:002017Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis.29686424Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JVNature medicineMechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018 05; 24(5):638-646.Nat Med2018-04-23T00:00:002018Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.29293386Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan RJournal of clinical oncology : official journal of the American Society of Clinical OncologyBayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822.J Clin Oncol2018-01-02T00:00:002018Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.30279957Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu SOncotargetOutcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget. 2018 Sep 07; 9(70):33258-33270.Oncotarget2018-09-07T00:00:002018Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer.D012178Disorders33880.917018Retinopathy of PrematurityAuthorship 9461341231037378Gunn GB, Mendoza TR, Garden AS, Wang XS, Shi Q, Morrison WH, Frank SJ, Phan J, Fuller CD, Chambers MS, Hanna EY, Lu C, Rosenthal DI, Cleeland CSSupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerMinocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Support Care Cancer. 2020 Jan; 28(1):261-269.Support Care Cancer2019-04-29T00:00:002019Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial.D065646Disorders742570.7937Thyroid Carcinoma, Anaplastic23169304Gunn GB, Mendoza TR, Fuller CD, Gning I, Frank SJ, Beadle BM, Hanna EY, Lu C, Cleeland CS, Rosenthal DIHead & neckHigh symptom burden prior to radiation therapy for head and neck cancer: a patient-reported outcomes study. Head Neck. 2013 Oct; 35(10):1490-8.Head Neck2012-11-20T00:00:002012High symptom burden prior to radiation therapy for head and neck cancer: a patient-reported outcomes study.23704207Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, Huang MS, Chang DW, Li Y, Pankratz VS, Minna JD, Hong WK, Hildebrandt MA, Hsiung CA, Yang PCancer researchGenome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Res. 2013 Jul 01; 73(13):4028-38.Cancer Res2013-05-23T00:00:002013Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers.Authorship 952186631319771Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas METhyroid : official journal of the American Thyroid AssociationComplete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043.Thyroid2019-08-01T00:00:002019Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.Authorship 953427731386610Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly KJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Na?ve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol. 2019 10 01; 37(28):2537-2547.J Clin Oncol2019-08-06T00:00:002019Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Na?ve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).Authorship 9617891231778797Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao ASJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerPhase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257.J Thorac Oncol2019-11-25T00:00:002019Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC.Authorship 9794561232193228Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JVClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.Clin Cancer Res2020-03-19T00:00:002020A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.Authorship 987932332327465Awobajo MD, Vaporciyan AA, Lu C, Gandhi SJBMJ case reportsStereotactic body radiation therapy (SBRT) in the management of pulmonary spindle cell carcinoma. BMJ Case Rep. 2020 Apr 22; 13(4).BMJ Case Rep2020-04-22T00:00:002020Stereotactic body radiation therapy (SBRT) in the management of pulmonary spindle cell carcinoma.Authorship 9892132032389639Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang JJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerProgrammed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.J Thorac Oncol2020-05-08T00:00:002020Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.Authorship 9953903432640131Bhasin S, Gill TM, Reuben DB, Latham NK, Ganz DA, Greene EJ, Dziura J, Basaria S, Gurwitz JH, Dykes PC, McMahon S, Storer TW, Gazarian P, Miller ME, Travison TG, Esserman D, Carnie MB, Goehring L, Fagan M, Greenspan SL, Alexander N, Wiggins J, Ko F, Siu AL, Volpi E, Wu AW, Rich J, Waring SC, Wallace RB, Casteel C, Resnick NM, Magaziner J, Charpentier P, Lu C, Araujo K, Rajeevan H, Meng C, Allore H, Brawley BF, Eder R, McGloin JM, Skokos EA, Duncan PW, Baker D, Boult C, Correa-de-Araujo R, Peduzzi P, STRIDE Trial InvestigatorsThe New England journal of medicineA Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries. N Engl J Med. 2020 07 09; 383(2):129-140.N Engl J Med2020-07-09T00:00:002020A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries.Authorship 996213632761153Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross ND, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo MJAMA oncologyEvaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020 09 01; 6(9):1397-1404.JAMA Oncol2020-09-01T00:00:002020Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019.Authorship 10051731733198942Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao ZJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerToxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol. 2021 02; 16(2):269-277.J Thorac Oncol2020-10-22T00:00:002020Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.Authorship 1010368933522021Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross NDHead & neckCytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603.Head Neck2021-02-01T00:00:002021Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck.Authorship 101180828Authorship 1012665633603241Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi BNature medicineNeoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.Nat Med2021-02-18T00:00:002021Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.33654695Jiang H, Zhang JC, Zeng J, Wang L, Wang Y, Lu CD, Deng L, Deng H, Wang K, Sun MW, Zhou P, Yuan T, Chen WBurns & traumaGut, metabolism and nutritional Support for COVID-19: Experiences from China. Burns Trauma. 2020; 8:tkaa048.Burns Trauma2020-12-21T00:00:002020Gut, metabolism and nutritional Support for COVID-19: Experiences from China.Authorship 102357217Authorship 10241581334241781Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing AAdvances in therapyPembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial. Adv Ther. 2021 08; 38(8):4581-4591.Adv Ther2021-07-09T00:00:002021Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial.34187851Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross NDClinical cancer research : an official journal of the American Association for Cancer ResearchPilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.Clin Cancer Res2021-06-29T00:00:002021Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.Authorship 1026879534358341Aggarwal P, Hutcheson KA, Garden AS, Mott FE, Lu C, Goepfert RP, Fuller CD, Lai SY, Gunn GB, Chambers MS, Sturgis EM, Hanna EY, Shete SCancerDeterminants of patient-reported xerostomia among long-term oropharyngeal cancer survivors. Cancer. 2021 12 01; 127(23):4470-4480.Cancer2021-08-06T00:00:002021Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors.Authorship 10384471Authorship 104021414Authorship 104080616Authorship 10418481635296449Lu C, Hanif A, Singh P, Chang K, Coyner AS, Brown JM, Ostmo S, Chan RVP, Rubin D, Chiang MF, Campbell JP, Kalpathy-Cramer J, Imaging and Informatics in Retinopathy of Prematurity Consortium Members of the Imaging and InformatOphthalmology. RetinaFederated Learning for Multicenter Collaboration in Ophthalmology: Improving Classification Performance in Retinopathy of Prematurity. Ophthalmol Retina. 2022 08; 6(8):657-663.Ophthalmol Retina2022-03-14T00:00:002022Federated Learning for Multicenter Collaboration in Ophthalmology: Improving Classification Performance in Retinopathy of Prematurity.35185150Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva MSignal transduction and targeted therapyActivation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022 02 21; 7(1):51.Signal Transduct Target Ther2022-02-21T00:00:002022Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.35365596Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva MSignal transduction and targeted therapyCorrection: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022 Apr 01; 7(1):110.Signal Transduct Target Ther2022-04-01T00:00:002022Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.35051703Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GRCancer treatment and research communicationsPhase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun. 2022; 30:100514.Cancer Treat Res Commun2022-01-07T00:00:002022Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.Authorship 10435292Authorship 104379418Authorship 104389213Authorship 10442238Authorship 10443921035419587Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross NDClinical cancer research : an official journal of the American Association for Cancer ResearchCorrection: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.Clin Cancer Res2022-04-14T00:00:002022Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.35413951Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva RNature communicationsDistinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970.Nat Commun2022-04-12T00:00:002022Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.35443062Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, Blumenschein G, Lu C, Johnson FM, Bell D, Lewis J, Zhang J, Feng L, Wilson K, Marcelo-Lewis K, Wang J, Ginsberg L, Gillison M, Lee JJ, Meric-Bernstam F, Mills GB, William WN, Myers JN, Pickering CRClinical cancer research : an official journal of the American Association for Cancer ResearchInduction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res. 2022 Apr 20.Clin Cancer Res2022-04-20T00:00:002022Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection.35391768Macruz FBC, Lu C, Strout J, Takigami A, Brooks R, Doyle S, Yun M, Buch V, Hedgire S, Ghoshhajra BRadiology. Artificial intelligenceQuantification of the Thoracic Aorta and Detection of Aneurysm at CT: Development and Validation of a Fully Automatic Methodology. Radiol Artif Intell. 2022 Mar; 4(2):e210076.Radiol Artif Intell2022-02-23T00:00:002022Quantification of the Thoracic Aorta and Detection of Aneurysm at CT: Development and Validation of a Fully Automatic Methodology.35459784Aggarwal P, Hutcheson KA, Yu R, Wang J, Fuller CD, Garden AS, Goepfert RP, Rigert J, Mott FE, Lu C, Lai SY, Gunn GB, Chambers MS, Li G, Wu CC, Hanna EY, Sturgis EM, Shete SScientific reportsGenetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Sci Rep. 2022 04 22; 12(1):6662.Sci Rep2022-04-22T00:00:002022Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors.Authorship 10504131835820397Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JVCancer cellPoziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 07 11; 40(7):754-767.e6.Cancer Cell2022-07-11T00:00:002022Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.Authorship 106022614Authorship 10551017Authorship 10568401136173224Liu H, Wang Y, Han Y, Yang G, Wang L, Peng J, Lu CD, Deng P, Liang H, Huang H, Jiang HAsia Pacific journal of clinical nutritionPretreatment optimization of tissue metabolomics in colorectal cancer. Asia Pac J Clin Nutr. 2022; 31(3):526-533.Asia Pac J Clin Nutr2022-01-01T00:00:002022Pretreatment optimization of tissue metabolomics in colorectal cancer.35977347Wang JR, Montierth M, Xu L, Goswami M, Zhao X, Cote G, Wang W, Iyer P, Dadu R, Busaidy NL, Lai SY, Gross ND, Ferrarotto R, Lu C, Gunn GB, Williams MD, Routbort M, Zafereo ME, Cabanillas MEJCO precision oncologyImpact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2022 08; 6:e2100504.JCO Precis Oncol2022-08-01T00:00:002022Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma.36371941Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SHLung cancer (Amsterdam, Netherlands)Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Oct 29; 174:112-117.Lung Cancer2022-10-29T00:00:002022Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial.Authorship 10634881736762947Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, Chasen NN, Vu T, Maniakas A, Eguia AA, Diersing J, Gross ND, Goepfert R, Lai SY, Hofmann MC, Ferrarotto R, Lu C, Gunn GB, Spiotto MT, Subbiah V, Williams MD, Cabanillas ME, Zafereo METhyroid : official journal of the American Thyroid AssociationSurgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid. 2023 04; 33(4):484-491.Thyroid2023-03-20T00:00:002023Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study.Authorship 10884491438311031Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O'Reilly MS, Gay CM, Altan M, Lu C, Cascone T, Koutroumpakis E, Sheshadri A, Zhang X, Liao L, Zhu XR, Heymach JV, Nguyen QN, Liao ZRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologySurvival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol. 2024 Apr; 193:110121.Radiother Oncol2024-02-03T00:00:002024Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma.Authorship 1090153638458791Ma W, Cai B, Wang Y, Wang L, Sun MW, Lu CD, Jiang HBMJ openArtificial intelligence driven malnutrition diagnostic model for patients with acute abdomen based on GLIM criteria: a cross-sectional research protocol. BMJ Open. 2024 Mar 08; 14(3):e077734.BMJ Open2024-03-08T00:00:002024Artificial intelligence driven malnutrition diagnostic model for patients with acute abdomen based on GLIM criteria: a cross-sectional research protocol.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessor24618342Sanchez-Espiridion B, Chen M, Chang JY, Lu C, Chang DW, Roth JA, Wu X, Gu JCancer researchTelomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians. Cancer Res. 2014 May 01; 74(9):2476-86.Cancer Res2014-03-11T00:00:002014Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians.24711162Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, Lu C, Garden AS, Morrison WH, Cleeland CS, Gunn GBCancerPatterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. Cancer. 2014 Jul 01; 120(13):1975-84.Cancer2014-04-07T00:00:002014Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module.24755914Pu X, Hildebrandt MA, Lu C, Roth JA, Stewart DJ, Zhao Y, Heist RS, Ye Y, Chang DW, Su L, Minna JD, Lippman SM, Spitz MR, Christiani DC, Wu XClinical pharmacology and therapeuticsInflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clin Pharmacol Ther. 2014 Sep; 96(3):360-369.Clin Pharmacol Ther2014-04-22T00:00:002014Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy.25104816Sheu T, Fuller CD, Mendoza TR, Garden AS, Morrison WH, Beadle BM, Phan J, Frank SJ, Hanna EY, Lu C, Cleeland CS, Rosenthal DI, Gunn GBOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck SurgeryNomogram for predicting symptom severity during radiation therapy for head and neck cancer. Otolaryngol Head Neck Surg. 2014 Oct; 151(4):619-26.Otolaryngol Head Neck Surg2014-08-07T00:00:002014Nomogram for predicting symptom severity during radiation therapy for head and neck cancer.